The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in sprague-dawley rats
The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Abstract
The effect of morphine tolerance and withdrawal on prodynorphin peptides was studied in relevant brain areas and in the pituitary gland of male Sprague-Dawley rats, and compared with effects on the proenkephalin-derived peptide Met-enkephalin. After 8 days of morphine injections (twice daily), dynorphin A and B levels increased in the nucleus accumbens and dynorphin A levels increased also in the striatum. Morphine treatment increased striatal Met-enkephalin. Leu-enkephalinArg6 levels were reduced in the ventral tegmental area (VTA). Morphine-treated rats had very low Leu-enkephalinArg6 levels in the hippocampus as compared to saline control rats. Comparison of the relative amounts of dynorphin peptides and the shorter prodynorphin-derived peptides, Leu-enkephalinArg6 and Leu-enkephalin, revealed a relative increase in dynorphin peptides versus shorter fragments in the nucleus accumbens, VTA and hippocampus. Morphine-tolerant rats had lower levels of dynorphin A in both lobes of the pituitary gland, whereas hypothalamic dynorphin levels were unaffected by morphine. Leu-enkephalinArg6 levels were reduced in the hypothalamus, but not changed in the pituitary gland. Naloxone-precipitated withdrawal accentuated the increase in dynorphin A and B levels in the accumbens and dynorphin A levels in the striatum, while inducing an increase in enkephalin levels in the accumbens and Met-enkephalin in the VTA. In the hippocampus, Leu-enkephalinArg6 levels remained low in the withdrawal st…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
A psychomotor stimulant theory of addiction.
Wise, R. A., & Bozarth, M. A. (1987) · Psychological Review · doi:10.1037/0033-295x.94.4.469 · Cited by 2,747
Cellular and molecular mechanisms of drug dependence
Koob, G. F., & Bloom, F. E. (1988) · Science · doi:10.1126/science.2903550 · Cited by 2,070
Molecular mechanisms of drug addiction
Nestler, E. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.06.031 · Cited by 1,108
Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.
Spanagel, R., Herz, A., & Shippenberg, T. S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2046 · Cited by 1,014
Di Chiara, G., & Imperato, A. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24578-5 · Cited by 916
Spanagel, R., Herz, A., & Shippenberg, T. S. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb04963.x · Cited by 539
Mucha, R. F., & Herz, A. (1985) · Psychopharmacology · doi:10.1007/bf00432213 · Cited by 510
Nestler, E. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-07-02439.1992 · Cited by 421
Weisskopf, M. G., Zalutsky, R. A., & Nicoll, R. A. (1993) · Nature · doi:10.1038/362423a0 · Cited by 336
Cited by
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337
“For opioids, animal studies have demonstrated region-specific increases in the levels of dynorphin after the passive administration of morphine (Nylander et al., 1995) and heroin (Weissman and Zamir, 1987).”
BackgroundAn essential role for ΔFosB in the nucleus accumbens in morphine action
Zachariou, V., Bolanos, C. A., Selley, D. E., Theobald, D., Cassidy, M. P., Kelz, M. B., Shaw-Lutchman, T., Berton, O., Sim-Selley, L. J., Dileone, R. J., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1636 · Cited by 266
Gardell, L. R., Wang, R., Burgess, S. E., Ossipov, M. H., Vanderah, T. W., Malan, T. P., Lai, J., & Porreca, F. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06747.2002 · Cited by 261
The dynorphin/κ-opioid receptor system and its role in psychiatric disorders
Tejeda, H. A., Shippenberg, T. S., & Henriksson, R. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0844-x · Cited by 179
“Like other drugs of abuse, opiate treatment has been shown to alter DYN/KOR systems in reward-related neural circuits in animal models [376].”
BackgroundSchlosburg, J. E., Whitfield, T. W., Park, P. E., Crawford, E. F., George, O., Vendruscolo, L. F., & Koob, G. F. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1979-13.2013 · Cited by 119
“Additionally, animal studies have demonstrated region-specific increases in gene expression of the precursor preprodynorphin (Tjon et al., 1997), leading to increased levels of dynorphin, following passive administration of morphine (Nylander et al., 1995) and heroin (Weissman and Zamir, 1987).”
BackgroundInfluentialContarino, A., & Papaleo, F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506999102 · Cited by 107
Nylander, I., Vlaskovska, M. V., & Terenius, L. Y. (1995) · Brain Research · doi:10.1016/0006-8993(95)00279-y · Cited by 93
Self-citationIn vivo detection of optically-evoked opioid peptide release
Al-Hasani, R., Wong, J.-M. T., Mabrouk, O. S., McCall, J. G., Schmitz, G. P., Porter-Stransky, K. A., Aragona, B. J., Kennedy, R. T., & Bruchas, M. R. (2018) · eLife · doi:10.7554/elife.36520 · Cited by 80
“mRNA levels and microdialysis of extracellular enkephalins in a number of brain regions including the nucleus accumbens (Nylander et al., 1995).”
BackgroundNegus, S. S., & Rice, K. C. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.127 · Cited by 70
“…exposure also activates systems that employ the neurotransmitters CRF (Iredale et al, 2000; Skelton et al, 2007) and dynorphin (Rattan et al, 1992; Nylander et al, 1995), and it has been proposed that increased activity in CRF and/or dynorphinergic systems may contribute to aversive states of…”
Dysregulation of dynorphins in Alzheimer disease
Yakovleva, T., Marinova, Z., Kuzmin, A., Seidah, N. G., Haroutunian, V., Terenius, L. Y., & Bakalkin, G. Y. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.07.002 · Cited by 72
Self-citationNylander, I., Stenfors, C., Tan–No, K., Mathé, A. A., & Terenius, L. Y. (1997) · Neuropeptides · doi:10.1016/s0143-4179(97)90072-x · Cited by 60
Self-citationGold, M. S., Baron, D., Bowirrat, A., & Blum, K. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.117137 · Cited by 57
“[157] showed a reduced leu-enkephalin in the VTA of Sprague Dawley rats with chronic morphine treatment.”
Genetic association analyses of PDYN polymorphisms with heroin and cocaine addiction
Clarke, T. ‐., Ambrose‐Lanci, L., Ferraro, T. N., Berrettini, W. H., Kampman, K. M., Dackis, C. A., Pettinati, H. M., O’Brien, C. P., Oslin, D. W., & Lohoff, F. W. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00785.x · Cited by 55
“As exposure to opioids and cocaine has been shown to induce neuroadaptive upregulation of PDYN expression (Frankel et al. 2008; Hurd & Herkenham 1995; Nylander et al. 1995; Solecki et al. 2009; Staley et al. 1997), it has been hypothesized that KOR antagonists could be effective drug therapies for addiction (Shippenbe…”
BackgroundSánchez-Cardoso, P., Higuera‐Matas, A., Martı́n, S., Olmo, N. D., Miguéns, M., Garcı́a-Lecumberri, C., & Ambrosio, E. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.011 · Cited by 55
Different affective response to opioid withdrawal in adolescent and adult mice
Hodgson, S. R., Hofford, R. S., Wellman, P. J., & Eitan, S. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.11.002 · Cited by 54
“Additionally, in adults, repeated morphine exposure and withdrawal induces changes in the expression of endogenous opioid ligands in different brain areas (Uhl et al., 1988; Yukhananov et al., 1993; Nylander et al., 1995a, b; Fukunaga et al., 1998; Van Bockstaele et al., 2000).”
BackgroundDynorphin and its role in alcohol use disorder
Karkhanis, A. N., & Al-Hasani, R. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146742 · Cited by 47
Lalanne, L., Ayrancı, G., Filliol, D., Gavériaux‐Ruff, C., Befort, K., Kieffer, B. L., & Lutz, P.-É. (2016) · Addiction Biology · doi:10.1111/adb.12392 · Cited by 46
“…& Terenius 1995a, 1995b); (ii) the timepoint, with an increase in the NAc after 4, but not 2weeks, of morphine withdrawal in mouse (Zan et al. 2015); and also (iii) genetic factors, with increased and decreased dynorphins in the VTA of Fischer and Lewis rats, respectively (Nylander et al. 1995a).”
BackgroundDivergent profiles of fentanyl withdrawal and associated pain in mice and rats
Uddin, O., Jenne, C. E., Fox, M. E., Arakawa, K., Keller, A., & Cramer, N. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173077 · Cited by 46
Olson, G. A., Olson, R. D., & Kastin, A. J. (1996) · Peptides · doi:10.1016/s0196-9781(96)00225-2 · Cited by 51
Torres-Reveron, A., Khalid, S., Williams, T. J., Waters, E. M., Jacome, L., Luine, V. N., Drake, C. T., McEwen, B. S., & Milner, T. A. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.12.023 · Cited by 42
“A single morphine injection has been shown to decrease DYN in the HF (Nylander et al., 1995) while exogenous opioid agonists increase DYN (Kiraly et al., 2006).”
BackgroundSolecki, W., Ziolkowska, B., Krowka, T., Gieryk, A., Filip, M., & Przewlocki, R. (2009) · Brain Research · doi:10.1016/j.brainres.2008.12.002 · Cited by 39
Kelsey, J. E., Verhaak, A. M. S., & Schierberl, K. C. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.01.008 · Cited by 36
Zan, G., Wang, Q., Wang, Y., Liu, Y., Hang, A., Shu, X. H., & Liu, J. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.05.053 · Cited by 45
The role of enkephalinergic systems in substance use disorders
Rysztak, L. G., & Jutkiewicz, E. M. (2022) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2022.932546 · Cited by 40
“, 1988) or increase met-enkephalin (Nylander et al., 1995) in the striatum, NAc, and PAG (Nieto et al.”
BackgroundShoblock, J. R., & Maidment, N. T. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.05.011 · Cited by 29
Suzuki, T., Tsuji, M., Mori, T., Misawa, M., & Nagase, H. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00319-x · Cited by 29
The effect of Paracetamol on nociception and dynorphin A levels in the rat brain
Sandrini, M., Romualdi, P., Capobianco, A., Vitale, G., Morelli, G., Pini, L. A., & Candeletti, S. (2001) · Neuropeptides · doi:10.1054/npep.2001.0852 · Cited by 27
Cappendijk, S. L. T., Hurd, Y. L., Nylander, I., van Ree, J. M., & Terenius, L. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00874-7 · Cited by 25
Self-citationLeconte, C., Mongeau, R., & Noble, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.856672 · Cited by 26
β-Phenylethylamines and the isoquinoline alkaloids
Bentley, K. W. (1997) · Natural Product Reports · doi:10.1039/np9971400387 · Cited by 26
Rossbach, U. L., Nilsson, A., Fälth, M., Kultima, K., Zhou, Q., Hallberg, M., Gordh, T., Andrén, P. E., & Nyberg, F. (2009) · Journal of Proteome Research · doi:10.1021/pr800669g · Cited by 25
Catheline, G., Kayser, V., Idänpään-Heikkilä, J. J., & Guilbaud, G. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00790-x · Cited by 24
Differential Metabolism of Dynorphins in Substantia Nigra, Striatum, and Hippocampus
Sandin, J., Tan–No, K., Kasakov, L., Nylander, I., Winter, A., Silberring, J., & Terenius, L. Y. (1997) · Peptides · doi:10.1016/s0196-9781(97)00025-9 · Cited by 23
Self-citationProtracted manifestations of acute dependence after a single morphine exposure
Rothwell, P. E., Thomas, M. J., & Gewirtz, J. C. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2425-y · Cited by 21
“A second possibility is that naloxone operates by antagonizing increased release of endogenous opioids after acute exposure to an exogenous opiate (Nylander et al. 1995; Olive et al. 1995).”
Shahkarami, K., Vousooghi, N., Golab, F., Mohsenzadeh, A., Baharvand, P., Sadat‐Shirazi, M., Babhadi‐Ashar, N., Shakeri, A., & Zarrindast, M. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107638 · Cited by 18
Király, K. P., Riba, P., D’Addario, C., Benedetto, M. D., Landuzzi, D., Candeletti, S., Romualdi, P., & Fürst, S. (2006) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2006.05.005 · Cited by 18
Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits
Davis, M. P. (2025) · Drugs · doi:10.1007/s40265-024-02128-y · Cited by 21
“Morphine increases dynorphin, an endogenous kappa receptor agonist, in the nucleus accumbens causing analgesic tolerance [148, 149].”
Altered Accumbal Dopamine Terminal Dynamics Following Chronic Heroin Self-Administration
George, B. E., Dawes, M. H., Peck, E. G., & Jones, S. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158106 · Cited by 20
Su, M., Lin, W., Lue, W.-M., Cheng, C., & Tao, P. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701646 · Cited by 16
Zhou, Q., Carlsson, A., Hallberg, M., & Nyberg, F. (2011) · Peptides · doi:10.1016/j.peptides.2011.06.030 · Cited by 15
Tan–No, K., Terenius, L. Y., Silberring, J., & Nylander, I. (1997) · Neurochemistry International · doi:10.1016/s0197-0186(96)00137-4 · Cited by 14
Self-citationA review of the kappa opioid receptor system in opioid use
Çayır, S., Zhornitsky, S., Barzegary, A., Carreño, E. S., Sarfo-Ansah, W., Funaro, M. C., Matuskey, D., & Angarita, G. A. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105713 · Cited by 16
“…1999; Wei et al., 2007; Yukhananov et al., 1993), or opposite results depending on the administration paradigm (single-low vs. repeated high doses) (Nylander et al., 1995b), rat strain (Fischer vs. Lewis) (Nylander et al., 1995a) and type of opioid (oxycodone vs. morphine) (Kir ´ aly et al., 2006).”
BackgroundInfluentialGeorgieva, J., Heilig, M. A., Nylander, I., Herrera‐Marschitz, M., & Terenius, L. Y. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11592-k · Cited by 13
Self-citationTolerance develops in spinal cord, but not in brain with chronic [Dmt1]DALDA treatment
Ben, Y., Smith, A. P., Schiller, P. W., & Lee, N. M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706007 · Cited by 12
“A similar lack of correlative changes has been reported with studies of opioid peptides at protein levels (Nylander et al., 1995; Trujillo & Akil, 1995) and at mRNA levels (Mocchetti et al., 1989; Gudehithlu & Bhargava, 1995; Tjon et al., 1997; Turchan et al., 1997; Fang et al., 1998).”
BackgroundOpiate modulation of dynorphin conversion in primary cultures of rat cerebral cortex
Vlaskovska, M. V., Nylander, I., Schramm, M., Hahne, S., Kasakov, L., Silberring, J., & Terenius, L. Y. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00307-7 · Cited by 10
Self-citationCharacterization of immunoreactive dynorphin B and β-endorphin in human plasma
Silberring, J., Li, Y.-M., Terenius, L. Y., & Nylander, I. (1998) · Peptides · doi:10.1016/s0196-9781(98)00079-5 · Cited by 7
Self-citationBroberger, C., Nylander, I., Geijer, T., Terenius, L. Y., Hökfelt, T., & Georgieva, J. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00276-4 · Cited by 7
Self-citationKappa opioid receptor control of motivated behavior revisited
Farahbakhsh, Z. Z., & Siciliano, C. A. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02226-9 · Cited by 10
“Congruent with a role in stress, dynorphin levels are also heightened in various brain regions during periods of withdrawal from ethanol [52, 146 – 148] and morphine [149].”
Kreibich, A. S., & Blendy, J. A. (2005) · International review of neurobiology · doi:10.1016/s0074-7742(04)65006-9 · Cited by 6
Franck, J., Nylander, I., & Rosén, A. (1996) · Neuropharmacology · doi:10.1016/0028-3908(96)84646-6 · Cited by 4
Self-citationOptimization and characterization of an opioid kappa receptor (OPRK1) antagonist
Guerrero, M., Urbano, M., Brown, S. J., Cayanan, C. S., Ferguson, J., Cameron, M. D., Devi, L. A., Roberts, E., & Rosen, H. (2014) · Europe PMC (PubMed Central) · Cited by 5
Brice‐Tutt, A. C., Eans, S. O., Yakovlev, D., Aldrich, J. V., & McLaughlin, J. P. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173405 · Cited by 3
Psychological and Psychiatric Consequences of Opiates
Gold, M. S., & Johnson, C. R. (1998) · Springer eBooks · doi:10.1007/978-1-4757-2913-9_25 · Cited by 2
Koob, G. F., Arends, M. A., McCracken, M. L., & Moal, M. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-816988-9.00001-1 · Cited by 2
Tolerance to Morphine Analgesia: Influence of Pain and Method of Morphine Delivery
Chen, S. A., & Vaccarino, A. L. (2000) · Pain Research and Management · doi:10.1155/2000/842034 · Cited by 2
Blum, K., Downs, B. W., Bagchi, D., Wang, G., Thanos, P. K., Elman, I., Jalali, R., Bowirrat, A., Baron, D. A., Soni, D., et al. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822238-6.00001-7 · Cited by 1
Persistent effects of repeated adolescent and adult heroin vapor inhalation in female Wistar rats
Gutierrez, A., & Taffe, M. A. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07175-9 · Cited by 1
Heroin Self-Administration Induces Altered Dopamine Terminal Dynamics in the Nucleus AccumbensPreprint
George, B. E., Dawes, M. H., Peck, E. G., & Jones, S. R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.02.478890 · Cited by 1
“Prior studies have shown that dynorphin and its precursors are elevated following opioid exposure[56-60], which suggests increased endogenous agonist activation of KORs.”
BackgroundPsychological and Psychiatrie Consequences of Opiates
Gold, M. S., & Johnson, C. R. (1998)
Mood disruption in heroin abstinence : mechanisms and gene discovery
Ayrancı, G. (2015) · theses.fr (ABES) · doi:10.70675/a956874cz8192z4eb4zb9dez3ceb46a28053
Metadata
- Authors
- Nylander, I., Vlaskovska, M., & Terenius, L.
- Affiliations
- Karolinska Institutet (SE)
- ORCID
- Terenius, L.
- Venue
- Psychopharmacology
- Published
- 1995-04
- Volume
- 118
- Issue
- 4
- Pages
- 391-400
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2044963578
- Cited by
- 61
- References
- 65
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 6 · 2020: 4 · 2019: 1 · 2018: 1 · 2016: 1 · 2015: 3 · 2014: 1 · 2013: 1 · 2012: 1
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Vetenskapsrådet
- National Institute on Drug Abuse
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- morphine tolerance, morphine withdrawal, dynorphin, enkephalin, prodynorphin, met-enkephalin, nucleus accumbens, ventral tegmental area, hippocampus, pituitary gland, striatum, naloxone-precipitated withdrawal, opioid peptides
- MeSH terms
- Analysis of Variance, Animals, Drug Tolerance, Dynorphins, Endorphins, Enkephalin, Leucine, Male, Morphine, Naloxone, Peptides, Substance Withdrawal Syndrome, Rats, Sprague-Dawley, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.